with us
together we’re making a difference

News Releases

Sep 03, 2024 |

Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio

Aug 29, 2024 |

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 16, 2024 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Aug 12, 2024 |

Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Aug 05, 2024 |

Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

Jul 16, 2024 |

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2024 |

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jun 25, 2024 |

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 18, 2024 |

Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting

Jun 17, 2024 |

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 27
News Resources
Print
IR Contact
RSS Feeds
Email Alerts
Contact Us

info@annexonbio.com
650.822.5500

Investors:
investors@annexonbio.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

Annexon Biosciences

1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005

© 2024 Annexon Inc. All rights reserved.